Champions Oncology：2025年季度报告

Form10-Q (Mark One) ☑QUARTERLY REPORT PURSUANT TO SECTION 13OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period endedJuly31, 2025 Or ☐TRANSITION REPORT PURSUANT TOSECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period fromto (Exact name of registrant as defined in its charter) (201)808-8400(Registrant’s telephone number, including area code) Not Applicable(Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Name of Each Exchange on Which RegisteredTheNasdaqStock Market LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and(2) has been subject to such filing requirements for the past 90 days.YesþNo¨ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuantto Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant wasrequired to submit such files).YesþNo¨ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” and “smallerreporting company”, and "emerging growth company" in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.o Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐NoþThe number of shares of common stock of the Registrant outstanding as of September 12, 2025 was13,788,421. DOCUMENTS INCORPORATED BY REFERENCE - None INDEX TO FORM 10-QFOR THE QUARTERLY PERIOD ENDED JULY31, 2025 PART I - FINANCIAL INFORMATIONItem 1.Financial Statements.Condensed Consolidated Balance Sheets as ofJuly31, 2025 (unaudited) and April 30, 20254Unaudited Condensed Consolidated Statements of Operations for the ThreeMonths EndedJuly31, 2025 and20245Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) for the ThreeMonths EndedJuly31, 2025 and 20246Unaudited Condensed Consolidated Statements of Cash Flows for theThreeMonths EndedJuly31, 2025 and20247Notes to UnauditedCondensedConsolidatedFinancialStatements8Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations19Item 3.Quantitative and Qualitative Disclosures About Market Risk23Item 4.Controls and Procedures23PART II - OTHER INFORMATIONItem 1.Legal Proceedings25Item 1A.Risk Factors25Item 2.Unregistered Sales of Equity Securities and Use of Proceeds25Item 3.Defaults Upon Senior Securities25Item 4.Mine Safety Disclosures25Item 5.Other Information25Item 6.Exhibits26 CHAMPIONS ONCOLOGY, INC.UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(Dollars in Thousands, Except Per Share Amounts) CHAMPIONS ONCOLOGY, INC.UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY(DEFICIENCY)(Dollars in Thousands) CHAMPIONS ONCOLOGY, INC.UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Dollars in Thousands) CHAMPIONS ONCOLOGY, INC.NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Note 1.Organization, Use of Estimates and Basis of Presentation Champions Oncology, Inc. (the "Company", or "we", or "our") is engaged in drug discovery and development through data-drivenresearch strategies and innovative pharmacology, biomarker and data platforms. The Company’s TumorGraft Technology Platform (the"Platform"), a comprehensive bank of unique, well characterized "Patient Derived XenoGrafts" (PDX) models, is an approach topersonalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The Company provides a technologyplatform to pharmaceutical and biotechnology companies using proprietary TumorGraft studies, which the Company believes may bepredictive of how drugs may perform in clinical settings. Utilizing the Platform, the Company offers multiple services to pharmaceuticaland biotechnology companies seeking personalized approaches to drug development. By performing studies to predict the efficacy ofoncology drugs, our Platform is designed to facilitate drug discovery with lower costs and increased speed of drug development as well asincreased adoption of existing drugs. The Company hasfouroperating subsidiaries: Champions Oncology (Israel), Limited, Champions Oncology U.K. Limited, ChampionsOncology, S.R.L. (Italy), and Corellia A.I.